Joint Committee on
Vaccination and Immunisation (JCVI) quotes
[2009 July] Conflicted Government Expert Airbrushes Embarrassing Autism Science
Professor Alan Emond author of a new study claiming to overturn the link between autism and bowel disease has failed to disclose his conflict of interest as member of the UK’s Joint Committee on Vaccination and Immunisation [JCVI Members]. A 1998 Lancet medical journal study first published the link and controversially suggested a possible cause might be the MMR vaccine: [Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children Lancet 1998:351;9103]. The JCVI decides UK MMR and other vaccination policy and was recently given sole legal power by the New Labour Government: [UK Government Hands Drug Industry Control of Childhood Vaccination].
In 2006 after infant Georgie Fisher died following MMR vaccination the infant’s father claims Professor Emond did not disclose JCVI membership to him and his wife when Emond was brought into the investigation by the coroner: [Georgie Boy MMR]. The Coroner subsequently discounted MMR as implicated in the death.
In 1988 the JCVI approved defective MMR vaccines and failed to call for withdrawal when large numbers of British children were seriously injured [British Government’s Reckless Disregard for Child Health Safety].
The 1998 Lancet study raising the link with autism and bowel disease has proven robust in a series of papers [cited below] despite being widely attacked in the media for suggesting a link with MMR vaccine and claimed to be “discredited”.
The chairman of the government committee that approved the inoculation is receiving financial support for his work from a company involved in its manufacture. Professor Michael Langman, who heads the Joint Committee on Vaccination and Immunisation, gets funding from Merck Sharp and Dohme (MSD) for his medical research at Birmingham University. [Media Aug 16, 2004] Five-in-one jab adviser has links to vaccine firm
"5 out of 6 members of the (UK) Joint Committee on Vaccination and Immunisation had interests with Glaxo Wellcome, 4 with SmithKline Beecham (ref: May 1999 Secretary of State for Health)
The person who commissioned
was Paul Nuki, Sunday Times' sometime Head of Newsroom investigations and
"Focus" editor. Paul Nuki is son of Professor George Nuki. Professor George Nuki
in 1987 sat on the Committee on Safety of Medicines when the CSM was considering
Glaxo company Smith Kline & French Laboratories' Pluserix MMR vaccine for safety
approval. ......sitting on the CSM with Professor George Nuki was Professor Sir Roy
Meadow and Professor Sir David Hull............it was Professor Sir David Hull in 1998 who, as chairman of the
Joint Committee on Vaccination and Immunisation, started the attacks on
"Four of the medical experts advising the Government on whether the new meningitis C vaccine is safe have links to one or more of the drug companies that produce it......Professor Janet Darbyshire, a member of the Government's Committee on Safety of Medicines, had received support for academic research from US firms Wyeth and Chiron, who produce the two main meningitis products being used on children in Britain....three members of the Joint Committee on Vaccination and Immunisation had declared interests in vaccine manufacturers...Dr David Goldblatt of the Institute of Child Health, has served on an expert advisory panel for Wyeth and received research grants from Wyeth and North American Vaccines, which produces a third meningitis C drug to be introduced this year. Another, Professor Keith Cartwright of the University of Bristol, received funding from the drug industry to 'evaluate candidate meningicoccal vaccines'. "--Martin Bright and Tracy McVeigh, Sunday Observer, UK September 3, 2000
"A Parliamentary Written Question by Mrs. Ann Winterton MP in May 1999 confirmed the following declared interests within the JCVI membership (NB - the PWQ related only to a limited range of pharmaceuticals companies, so the full list will be greater than this): Professor Lewis Ritchie (Glaxo Wellcome), Dr. Barbara Bannister (Glaxo Wellcome and SmithKline Beecham), Dr. David Goldblatt (SmithKline Beecham), Dr. Diana Walford (Glaxo Wellcome and SmithKline Beecham), Professor Roy Anderson (Glaxo Wellcome and SmithKline Beecham), Dr. Karl Nicholson (Glaxo Wellcome)"--David Thrower Flawed UK Regulatory and Monitoring Systems (2001)
The Chairman reminded members that the proceedings, papers, and information before them were confidential and should not be disclosed
Investigations Completed July 2003 - June 2004
Department of Health Refusal to provide
information about the awarding of a contract to supply a stock of smallpox
Ms Branigan originally asked DoH for a number of pieces of information relating to the awarding of a contract to PowderJect Technologies PLC to supply a stock of smallpox vaccine. She then asked 17 Government Departments, including DoH, for information relating to contacts between their respective Ministers and representatives of PowderJect. Finally, she asked DoH for several pieces of information relating to the work of the sub- group of the Joint Committee on Vaccination and Immunisation, which had given advice on the choice of the particular smallpox vaccine strain. DoH declined to release most of the information sought by Ms Branigan and cited a number of code exemptions in justification. After a protracted investigation, beset by DoH delays, the Ombudsman recommended that almost all the information sought by Ms Branigan be released. Following a further exchange of correspondence, DoH agreed to the release of information which had already entered the public domain but either refused to address the remaining recommendations or refused to release the information recommended for disclosure. The Ombudsman criticised the manner in which DoH had handled Ms Branigan's information requests and for their failure to engage effectively with her own investigation.
.......In respect of the letter of 29 May 2002, DoH: have continued to refuse to confirm the identities of the second and third members of the JCVI sub-group even though the identity of the second member is already in the public domain ; have refused to release the names of the organisations to whom the other members of the sub-group belonged, and have apparently refused to release the information contained in the document headed 'Main Points', which summarises that meeting.